Van Morris, MD
Dr. Morris is an Associate Professor in the Department of Gastrointestinal Medical Oncology at the University of Texas – MD Anderson Cancer Center in Houston, TX. His clinical practice focuses on the treatment of colorectal and anal cancers, and he has written multiple clinical trials which incorporate novel therapeutic approaches involving targeted therapies and immunotherapy. His work has been featured in publications in the New England Journal of Medicine, Lancet Oncology, Cancer Discovery, JAMA Oncology, and the Journal of Clinical Oncology. His research has been supported as a recipient of the ASCO Young investigator Award, NIH/NCI K12 Award, Khalifa Scholar Award, SWOG Hope Foundation Award, NIH/NCI Colorectal Cancer SPORE Early Career Award, Sabin Family Foundation Award, and a CPRIT Individual Investigator Research Award. He is currently the overall Principal Investigator for the NRG GI005 and SWOG S2107 trials.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:Colorectal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BMSTopic:Colorectal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovartisTopic:colorectal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BioNTechTopic:colorectal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:EMD SeronoTopic:colorectal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BicaraTopic:Anal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:IncyteTopic:Anal cancerDate added:05/02/2023Date updated:05/02/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RegeneronTopic:Colorectal cancerDate added:05/02/2023Date updated:05/02/2023